Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2002
04/23/2002US6376240 Nucleic acid has a nucleotide sequence encoding rflat-1, a zinc finger transcription factor; expression cassette
04/23/2002US6376236 Alphavirus vector construct which directs the expression of a heterologous nucleic acid molecule; capsid protein; and envelope glycoprotein from a second virus different from the alphavirus of said alphavirus vector construct
04/23/2002US6376224 Composition comprising inhibitor for membrane pumps and photoaffinity-labeled chemotherapeutic agent
04/23/2002US6376217 Fusion protein comprising gelonin amino acid sequence having enzymatic activity and antibody, antigen-binding fragment, hormone, lymphokine or growth factor targeting sequence allowing internalization of fusion protein
04/23/2002US6376214 DNA encoding a novel homolog of CSBP/p38 MAP kinase
04/23/2002US6376198 Screening with enhanced chimeric g protein-coupled peptide hormone receptor that signals through wild-type pathway, in which region of functional domain of one peptide hormone receptor is replaced with corresponding region of another
04/23/2002US6376196 Contacting sample with isolated immunodominant neospora antigen, thereby forming antigen/antibody complex and detecting presence of antibodies specifically immunoreactive with bovine neospora antigen
04/23/2002US6376174 Nucleic acid encoding Schwannomin-Binding-Proteins and products related thereto
04/23/2002US6375989 Submucosa extracts
04/23/2002US6375985 System and method for producing drug-loaded microparticles
04/23/2002US6375975 Pharmaceutical compositions for buccal and pulmonary application
04/23/2002US6375955 Peptides
04/23/2002US6375953 Treatment of infectious diseases with HSP70-peptide complexes
04/23/2002US6375952 Isolated herpes simplex virus polypeptide
04/23/2002US6375950 Methods for inducing T cell unresponsiveness to donor tissue or organ in a recipient with gp39 antagonists
04/23/2002US6375948 Treating method for suppressing hair growth
04/23/2002US6375947 Recombinant kid pregastric esterase and methods for its production and use
04/23/2002US6375946 Antitumor, viricides,nk cell activating cytokine or a nk cell activating flavonoid and a compound effective to inhibit the production or release of hydrogen peroxide selected from the group consisting of histamine, other h.sub.2 receptor
04/23/2002US6375944 Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
04/23/2002US6375942 Petrolatum, wax, antibiotic, zinc oxide and anit-itch
04/23/2002US6375929 Gene therapy for inhibition of angiogenesis
04/23/2002US6375928 Neutrophil stimulating peptides
04/23/2002CA2300386C Method for treating dystonia with botulinum toxin types c,d and e
04/23/2002CA2191714C Therapeutic food composition and method to diminish blood sugar fluctuations
04/23/2002CA2166312C Compositions for nasal administration of desmopressin
04/23/2002CA2004127C Novel aminobenzoates
04/18/2002WO2002031512A2 Molecular interactions in hematopoietic cells
04/18/2002WO2002031499A1 Detection of neurodegenerative disorders
04/18/2002WO2002031498A2 Protecting therapeutic compositions from host-mediated inactivation
04/18/2002WO2002031208A1 Method for identifying type 2 hypercarbic respiratory failure associated with community acquired pneumonia
04/18/2002WO2002031198A2 Cancer-linked genes as targets for chemotherapy
04/18/2002WO2002031180A2 Flea peritrophin nucleic acid molecules, proteins and uses thereof
04/18/2002WO2002031163A1 Novel adamts family polypeptide and gene encoding the same
04/18/2002WO2002031162A2 Regulation of human phospholipase a2-like enzyme
04/18/2002WO2002031161A2 Regulation of human phospholipase-like enzyme
04/18/2002WO2002031160A2 Regulation of human phospholipase a2-like enzyme
04/18/2002WO2002031156A2 Bvh-a2 and bvh-a3 antigens of group b streptococcus
04/18/2002WO2002031152A2 Intracellular signaling molecules
04/18/2002WO2002031151A2 Lipocalins
04/18/2002WO2002031149A2 Polyvalent cation-sensing receptor proteins in aquatic species
04/18/2002WO2002031146A2 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
04/18/2002WO2002031145A1 Novel g protein-coupled receptor protein and dna thereof
04/18/2002WO2002031144A2 Identification of cytotoxic activity from the ink of aplysia punctata
04/18/2002WO2002031143A2 Nucleic acid sequences encoding cmg proteins cmg proteins and methods for their use
04/18/2002WO2002031142A2 Antisense nucleic acid against alphav integrin
04/18/2002WO2002031141A2 Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
04/18/2002WO2002031138A1 Paramyxovirus vector for transferring foreign gene into skeletal muscle
04/18/2002WO2002031128A1 Methods of agonizing and antagonizing fabk
04/18/2002WO2002031126A2 Regulation of human cyclophilin-type peptidyl-prolyl cis-trans isomerase
04/18/2002WO2002031125A2 Human phospholipase a2-like enzyme
04/18/2002WO2002031117A2 Clasp-2 transmembrane proteins
04/18/2002WO2002031116A2 Gene expression modulated in spontaneous inflammatory bowel disease
04/18/2002WO2002031115A2 Nucleic acid molecules and polypeptides for immune modulation
04/18/2002WO2002031114A2 Gene expression modulated in ileitis
04/18/2002WO2002031110A2 Hematopoietic stem cell gene therapy
04/18/2002WO2002031109A2 Intracellular delivery of biological effectors by novel transporter peptide sequences
04/18/2002WO2002031025A2 Biodegradable poly(beta-amino esters) and uses thereof
04/18/2002WO2002030983A2 Plasma fraction containing bikunin, method for the production thereof and use of the same
04/18/2002WO2002030982A2 Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
04/18/2002WO2002030980A2 Use of anti-human integrin alpha d antibodies to treat spinal cord injury
04/18/2002WO2002030979A2 Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same
04/18/2002WO2002030978A1 Polypeptides, methods of making, and uses thereof
04/18/2002WO2002030976A1 Cell control nucleic acids and proteins
04/18/2002WO2002030975A2 Antifungal peptides
04/18/2002WO2002030972A2 Regulation of nf-at interacting protein nip 45 like protein
04/18/2002WO2002030970A2 Human histone deacetylase gene
04/18/2002WO2002030969A2 Regulation of human carboxylesterase-like enzyme
04/18/2002WO2002030968A1 Novel mite allergens and uses therefor
04/18/2002WO2002030957A1 Peptide-based gemini surfactant compounds facilitating the transfer into cells
04/18/2002WO2002030956A1 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
04/18/2002WO2002030955A2 Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use
04/18/2002WO2002030922A2 Dioxolane analogs for improved inter-cellular delivery
04/18/2002WO2002030889A2 A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
04/18/2002WO2002030887A2 Protein having thrombolytic activities extracted from natural product
04/18/2002WO2002030873A1 Mmp inhibitor
04/18/2002WO2002030470A1 Methods and compositions for nucleic acid delivery
04/18/2002WO2002030468A1 Complexes for transferring nucleic acids into cells
04/18/2002WO2002030465A2 Compositions that inhibit proliferation of cancer cells
04/18/2002WO2002030464A1 Novel drugs for liver diseases
04/18/2002WO2002030463A2 Reduced-viscosity concentrated protein formulations
04/18/2002WO2002030462A2 Hedgehog antagonists, methods and uses related thereto
04/18/2002WO2002030455A2 Agents for the treatment of viral infections
04/18/2002WO2002030454A1 Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype
04/18/2002WO2002030453A1 Methods of inhibiting angiogenesis using nadph oxidase inhibitors
04/18/2002WO2002030451A1 Compositions and methods for reducing gnrh-induced bone loss
04/18/2002WO2002030450A1 Use of d-leu deltorphin for protection against ischemia and reperfusion injury
04/18/2002WO2002030448A2 Treatment of demyelinating diseases by administering gpe
04/18/2002WO2002030447A2 Treatment of demyelinating diseases by administering gpe
04/18/2002WO2002030446A2 Reduction or prevention of post-surgical adhesion formation with fibrinogen
04/18/2002WO2002030445A2 Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation
04/18/2002WO2002030444A2 Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
04/18/2002WO2002030443A2 Regulation of human skin healing
04/18/2002WO2002030442A2 Use of [d-leu2]-deltrophin for treating cytokine mediated hgepatic injury
04/18/2002WO2002030441A2 Treatment of cancers by aplidine in conjunction with a myoprotector
04/18/2002WO2002030435A1 Treatment of t cell disorders
04/18/2002WO2002030434A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
04/18/2002WO2002030421A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/18/2002WO2002030396A1 Medication delivery devices
04/18/2002WO2002030393A2 Polymeric delivery formulations of leuprolide with improved efficacy
04/18/2002WO2002030371A1 Dyeing composition promoting natural pigmentation, method for obtaining same and use for colouring the skin and/or keratinous fibres